WO1999019357A3 - Cell regulatory genes, encoded products, and uses related thereto - Google Patents

Cell regulatory genes, encoded products, and uses related thereto Download PDF

Info

Publication number
WO1999019357A3
WO1999019357A3 PCT/US1998/021992 US9821992W WO9919357A3 WO 1999019357 A3 WO1999019357 A3 WO 1999019357A3 US 9821992 W US9821992 W US 9821992W WO 9919357 A3 WO9919357 A3 WO 9919357A3
Authority
WO
WIPO (PCT)
Prior art keywords
regulatory genes
cell regulatory
encoded products
uses related
transactivation
Prior art date
Application number
PCT/US1998/021992
Other languages
French (fr)
Other versions
WO1999019357A2 (en
WO1999019357A9 (en
Inventor
Annie Yang
Frank Mckeon
Original Assignee
Harvard College
Annie Yang
Frank Mckeon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Annie Yang, Frank Mckeon filed Critical Harvard College
Priority to AU10996/99A priority Critical patent/AU1099699A/en
Priority to US09/529,583 priority patent/US7030227B1/en
Publication of WO1999019357A2 publication Critical patent/WO1999019357A2/en
Publication of WO1999019357A3 publication Critical patent/WO1999019357A3/en
Publication of WO1999019357A9 publication Critical patent/WO1999019357A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This application describes the cloning of p63, a gene at chromosome 3q27-29, that bears homology to the tumor suppressor p53. The p63 gene encodes at least six different isotypes. p63 was detected in a variety of human and mouse tissue and demonstrates remarkably divergent activities, such as the ability to transactivate p53 reporter genes and induce apoptosis. Isotopes of p63 lacking a transactivation domain act as dominant negatives towards the transactivation by p53 and p63.
PCT/US1998/021992 1997-10-15 1998-10-02 Cell regulatory genes, encoded products, and uses related thereto WO1999019357A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU10996/99A AU1099699A (en) 1997-10-15 1998-10-02 Cell regulatory genes, encoded products, and uses related thereto
US09/529,583 US7030227B1 (en) 1997-10-15 1998-10-15 Cell regulatory genes, encoded products, and uses related thereto

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6207697P 1997-10-15 1997-10-15
US60/062,076 1997-10-15
US8721698P 1998-05-29 1998-05-29
US60/087,216 1998-05-29

Publications (3)

Publication Number Publication Date
WO1999019357A2 WO1999019357A2 (en) 1999-04-22
WO1999019357A3 true WO1999019357A3 (en) 1999-08-05
WO1999019357A9 WO1999019357A9 (en) 1999-09-02

Family

ID=26741834

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/021992 WO1999019357A2 (en) 1997-10-15 1998-10-02 Cell regulatory genes, encoded products, and uses related thereto

Country Status (2)

Country Link
AU (1) AU1099699A (en)
WO (1) WO1999019357A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030227B1 (en) 1997-10-15 2006-04-18 President & Fellows Of Harvard College Cell regulatory genes, encoded products, and uses related thereto
US7294459B1 (en) 1997-10-15 2007-11-13 President And Fellows Of Harvard College Cell regulatory genes, encoded products, and uses related thereto
US6476206B1 (en) 1998-03-27 2002-11-05 The Johns Hopkins University p40 protein acts as an oncogene
EP1847607B1 (en) 1998-03-27 2011-06-08 Otsuka Pharmaceutical Co., Ltd. Antibodies against the p51 protein
DE19822985C1 (en) * 1998-05-25 2000-01-13 Fraunhofer Ges Forschung P53 family tumor suppressor genes
DE10006033B4 (en) 2000-02-10 2005-11-10 Professor Dr. Magnus von Knebel Doeberitz Chirurgische Universitätsklinik Sektion für Molekulare Diagnostik und Therapie Immunization of an individual against carcinomas and their precursors
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
US6713257B2 (en) 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
CN1342662A (en) * 2000-09-12 2002-04-03 上海博德基因开发有限公司 Polypeptide-development regulation associated protein 10.01 and polynucleotide for coding it
PL1838350T3 (en) * 2005-01-20 2015-02-27 Ryboquin Company Ltd Modulators of itch ubiquitinase activity
WO2011090741A2 (en) 2009-12-29 2011-07-28 Opko Curna, Llc TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028186A1 (en) * 1996-02-02 1997-08-07 Sanofi PURIFIED SR-p70 PROTEIN

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028186A1 (en) * 1996-02-02 1997-08-07 Sanofi PURIFIED SR-p70 PROTEIN

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHMALE H, BAMBERGER C.: "A novel protein with strong homology to the tumor suppressor p53", ONCOGENE, vol. 15, no. 11, September 1997 (1997-09-01), pages 1363 - 1367, XP002101717 *
YANG A. ET AL.: "p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death inducing, and dominant-negative activities", MOLECULAR CELL, vol. 2, no. 3, September 1998 (1998-09-01), pages 305-316, XP002101716 *

Also Published As

Publication number Publication date
AU1099699A (en) 1999-05-03
WO1999019357A2 (en) 1999-04-22
WO1999019357A9 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
WO2004014314A3 (en) Methods and compositions concerning poxviruses and cancer
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
NO20000265L (en) Controlled cytolysis of target cells, agents and compositions that cause cytolysis and compounds that can be used to prepare the agents
WO2002087419A3 (en) Biological pacemaker
WO1996017626A3 (en) Water soluble ubiquinone compositions, prodrugs, and methods relating thereto
WO1999019357A3 (en) Cell regulatory genes, encoded products, and uses related thereto
WO2003000038A3 (en) Compositions and methods for modulating plant development
EP1201639A3 (en) Lipoxin compounds and their use in treating cell proliferative disorders
MX9703621A (en) Novel amino acid derivatives with improved multi-drug resistance activity.
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
MXPA01012336A (en) Silicone gel containing salicylic acid.
AU2386201A (en) Substituted sapogenins and their use
EP0247167A4 (en) Hydroxy and aminothiazolyl-benzodiazinone compounds, cardiotonic compositions including the same, and their uses.
IL118269A0 (en) Tetralin derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
BR0318278A (en) aminocyclohexyl ether compounds and uses thereof
PT1141315E (en) Modified hiv env polypeptides
AU5690196A (en) 1h-pyrrol-1-yl and 1h-indol-1-yl aryl sulphones, processes f or their preparation and use for the therapy of hiv-1 infect ions
AU8036598A (en) Titanium oxide-based photocatalyst, process for preparing the same, and use thereof
HUP0204449A3 (en) Oncolytic combinations for the treatment of cancer, containing 2',2'-difluoronucleoside and leukotriene antagonist as active ingredients
AU3052799A (en) Pharmaceutical compositions comprising erythropoietin for treatment of cancer
AU2525301A (en) Genus leontopodium plant extract and compositions containing same
AU1450592A (en) Use of deprenyl to maintain, prevent loss, or recover nerve cell function
MX9504023A (en) Transdermally active pharmaceutical composition containing 5-aminolaevulinic acid.
WO2000062741A3 (en) Skin care compositions containing combination of skin care actives
AU6738587A (en) Benzodiazinone-pyridazinone and hydroxy-pyrazolyl compounds, cardiotonic compositions including the same, and their uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/34-34/34, DRAWINGS, REPLACED BY NEW PAGES 1/39-39/39; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09529583

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA